Literature DB >> 26387754

ELABELA Is an Endogenous Growth Factor that Sustains hESC Self-Renewal via the PI3K/AKT Pathway.

Lena Ho1, Shawn Y X Tan2, Sheena Wee3, Yixuan Wu2, Sam J C Tan2, Navin B Ramakrishna2, Serene C Chng2, Srikanth Nama2, Iwona Szczerbinska, Iwona Sczerbinska4, Yun-Shen Chan4, Stuart Avery2, Norihiro Tsuneyoshi2, Huck Hui Ng4, Jayantha Gunaratne3, N Ray Dunn2, Bruno Reversade5.   

Abstract

ELABELA (ELA) is a peptide hormone required for heart development that signals via the Apelin Receptor (APLNR, APJ). ELA is also abundantly secreted by human embryonic stem cells (hESCs), which do not express APLNR. Here we show that ELA signals in a paracrine fashion in hESCs to maintain self-renewal. ELA inhibition by CRISPR/Cas9-mediated deletion, shRNA, or neutralizing antibodies causes reduced hESC growth, cell death, and loss of pluripotency. Global phosphoproteomic and transcriptomic analyses of ELA-pulsed hESCs show that it activates PI3K/AKT/mTORC1 signaling required for cell survival. ELA promotes hESC cell-cycle progression and protein translation and blocks stress-induced apoptosis. INSULIN and ELA have partially overlapping functions in hESC medium, but only ELA can potentiate the TGFβ pathway to prime hESCs toward the endoderm lineage. We propose that ELA, acting through an alternate cell-surface receptor, is an endogenous secreted growth factor in human embryos and hESCs that promotes growth and pluripotency.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26387754     DOI: 10.1016/j.stem.2015.08.010

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  54 in total

1.  Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin.

Authors:  Sophie Le Gonidec; Carline Chaves-Almagro; Yushi Bai; Hye Jin Kang; Allyson Smith; Estelle Wanecq; Xi-Ping Huang; Hervé Prats; Bernard Knibiehler; Bryan L Roth; Larry S Barak; Marc G Caron; Philippe Valet; Yves Audigier; Bernard Masri
Journal:  FASEB J       Date:  2017-02-27       Impact factor: 5.191

2.  Wnt signaling promotes hindgut fate commitment through regulating multi-lineage genes during hESC differentiation.

Authors:  Xiujuan Zhang; Ying Chen; Ying Ye; Jianfeng Wang; Hong Wang; Guohong Yuan; Zhe Lin; Yihui Wu; Yan Zhang; Xinhua Lin
Journal:  Cell Signal       Date:  2016-09-29       Impact factor: 4.315

3.  Is ELABELA a reliable biomarker for hypertensive disorders of pregnancy?

Authors:  Rong Huang; Jing Zhu; Lin Zhang; Xiaolin Hua; Weiping Ye; Chang Chen; Kun Sun; Weiye Wang; Liping Feng; Jun Zhang
Journal:  Pregnancy Hypertens       Date:  2019-06-27       Impact factor: 2.899

Review 4.  The emerging roles of circular RNAs in regulating the fate of stem cells.

Authors:  Ziyao Zhuang; Lingfei Jia; Weiran Li; Yunfei Zheng
Journal:  Mol Cell Biochem       Date:  2020-09-11       Impact factor: 3.396

Review 5.  Vascular effects of apelin: Mechanisms and therapeutic potential.

Authors:  Amreen Mughal; Stephen T O'Rourke
Journal:  Pharmacol Ther       Date:  2018-05-25       Impact factor: 12.310

6.  ELABELA and an ELABELA Fragment Protect against AKI.

Authors:  Hong Chen; Lin Wang; Wenjun Wang; Cheng Cheng; Yu Zhang; Yu Zhou; Congyi Wang; Xiaoping Miao; Jiao Wang; Chao Wang; Jianshuang Li; Ling Zheng; Kun Huang
Journal:  J Am Soc Nephrol       Date:  2017-06-05       Impact factor: 10.121

Review 7.  Apelinergic System Structure and Function.

Authors:  Kyungsoo Shin; Calem Kenward; Jan K Rainey
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

8.  ELABELA antagonizes intrarenal renin-angiotensin system to lower blood pressure and protects against renal injury.

Authors:  Chuanming Xu; Fei Wang; Yanting Chen; Shiying Xie; Danielle Sng; Bruno Reversade; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-16

9.  Alternative Progenitor Cells Compensate to Rebuild the Coronary Vasculature in Elabela- and Apj-Deficient Hearts.

Authors:  Bikram Sharma; Lena Ho; Gretchen Hazel Ford; Heidi I Chen; Andrew B Goldstone; Y Joseph Woo; Thomas Quertermous; Bruno Reversade; Kristy Red-Horse
Journal:  Dev Cell       Date:  2017-09-07       Impact factor: 12.270

10.  A Tale of Two Elabela Null Mice.

Authors:  Irinna Papangeli; Hyung J Chun
Journal:  Trends Endocrinol Metab       Date:  2017-09-27       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.